AN2 Therapeutics
ANTX
38 hedge funds and large institutions have $165M invested in AN2 Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
128% more capital invested
Capital invested by funds: $72.4M → $165M (+$92.6M)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
6% more funds holding
Funds holding: 36 → 38 (+2)
0.57% more ownership
Funds ownership: 48.39% → 48.95% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$633K |
| 2 |
Citigroup
New York
|
+$545K |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$293K |
| 4 |
Barclays
London,
United Kingdom
|
+$261K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$363K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$225K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$225K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$165K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$119K |
ANTX Hedge Fund Activity: Q3 2022 in Review
38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q3 2022, worth a combined $165M — up 128% from $72.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANTX positions and 1 closed out — a net gain of 2 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Avidity Partners Management, adding an estimated $633K. The largest seller was Woodline Partners, cutting an estimated $363K.
- 38 institutional investors held AN2 Therapeutics (ANTX) as of Q3 2022, up from 36 in Q2 2022.
- Funds reported $165M of AN2 Therapeutics stock for Q3 2022, up 128% quarter-over-quarter.
- 3 funds opened new AN2 Therapeutics positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest AN2 Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $633K added.
- The largest AN2 Therapeutics seller in Q3 2022 was Woodline Partners, an estimated $363K sold.
Based on aggregated 13F filings for Q3 2022.